HSK21542, a novel kappa opioid receptor agonist, demonstrated statistically significant superiority over placebo in reducing postoperative pain intensity in two phase 3 trials involving 658 patients across 47 centers in China.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.